Project Grant R41CA287830
Award Date
8/6/24
Completion Date
8/5/25
Dollars Obligated
$339K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Virginia, USA
Similar Awards
This federal Project Grant award of $269,280 from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports research to determine the biological effects and antitumor activity of a senescent cell-targeted antibody, SIWA318, in preclinical models of pancreatic ductal adenocarcinoma (PDAC). The research aims to evaluate whether depletion of senescent and pro-fibrotic cells in the PDAC tumor microenvironment can improve the efficacy of standard-of-care...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $674,275 in funding to Marker Therapeutics Inc., a small disadvantaged biotechnology company, to conduct a Phase 1 clinical study evaluating the safety and efficacy of their MT-601 multi-tumor associated antigen-specific T-cell therapy in patients with metastatic pancreatic cancer. The study aims to assess the clinical outcomes of combining MT-601 with frontline FOLFIRINOX chemotherapy,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $667,118.00 to The Regents of the University of California, San Francisco to conduct research aimed at "Identifying and Disabling New Pathways for Macromolecular Recycling in Pancreatic Cancer". The 5-year project, beginning on April 1, 2025, will systematically analyze pancreatic cancer cell lysosomes to identify key proteins that enable pro-survival catabolic...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,835 to Cambium Oncology LLC to develop a novel CAR-T immunotherapeutic for the treatment of pancreatic cancer. The key products to be delivered include: Engineering CAR-T cells that target the MUC16 antigen and secrete a VIP receptor antagonist (ANT308-FC) to disrupt the immunosuppressive tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC). This aims to enhance the...
The National Cancer Institute (NCI) awarded a Project Grant, under CFDA 93.394 Cancer Detection and Diagnosis Research, to Case Western Reserve University (CWRU) for $654,681 starting on December 1, 2024. The goal of this 5-year project is to develop innovative anticancer nanovaccines utilizing multifunctional ionizable lipid nanoparticles for the curative treatment of pancreatic ductal adenocarcinoma (PDAC). The research aims to design and evaluate these nanovaccines, assess their therapeutic...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $642,755 to The Institute For Cancer Research (ICR) to conduct research on targeting the protein Anoctamin 6 (ANO6) to disrupt the process of trogocytosis between cancer-associated fibroblasts (CAFs) and pancreatic ductal adenocarcinoma (PDAC) tumor cells. The key objectives are to understand how ANO6 activity is regulated in the CAF-cancer cell interface, determine how blocking...
This $1,130,538 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a targeted therapeutic strategy against metastatic pancreatic ductal adenocarcinoma (PDAC) using a newly developed anti-Tn (AREMAB6) monoclonal antibody. The key objectives are to: 1) determine how the Tn antigen enhances PDAC progression and identify Tn-expressing glycoproteins; 2) validate the role of natural killer cells in AREMAB6-mediated...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $677,176 to The Research Foundation For The State University Of New York (RF SUNY) to advance the development of interstitial chemophototherapy (I-CPT) as a novel treatment approach for locally advanced pancreatic cancer (PACA). The key products and services to be delivered under this 4-year award include: Defining optimal I-CPT light dosimetry for treating large PACA tumors...
The National Cancer Institute (NCI) awarded a $406,258 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Georgia State University Research Foundation Inc. on July 15, 2025. The grant supports research to develop novel covalent anti-cancer drugs using phosphorus fluoride exchange (PFEX) click chemistry. The key objectives are to: 1) synthesize PFEX warheads with different substituents to optimize stability and reactivity, 2) compare PFEX warheads to α,β-unsaturated carbonyl warheads,...
This federal Project Grant award of $395,724, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research to develop a novel class of anti-cancer therapeutics known as "Abbapolins" that target the Polo-like Kinase 1 (PLK1) protein. The research aims to optimize Abbapolin lead compounds and investigate their activity against colorectal cancers, including testing them on patient-derived organoid models. The award was...